EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Shawn G Kwatra, Gil Yosipovitch, Franz J Legat, Adam Reich, Carle Paul, Dagmar Simon, Luigi Naldi, Charles Lynde, Marjolein S De Bruin-Weller, Walter K Nahm, Maxwell Sauder, Rola Gharib und 13 weitere

New England Journal of Medicine · 26.10.2023 · 389 (17) · 1579-1589

DOI: 10.1056/nejmoa2301333 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 26.10.2023. Verfasst von Shawn G Kwatra und 24 weiteren Autor:innen. Beteiligte Einrichtung: From Johns Hopkins Itch Center, Johns Hopkins University School of Medicine, Baltimore (S.G.K.); the Miami Itch Center, Miller School of Medicine at …. Hauptthemen laut MEDLINE: Prurigo, Receptors, Interleukin, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 203-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Galderma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrurigoReceptors, InterleukinAntibodies, Monoclonal, HumanizedAdultHumansDermatitis, AtopicDouble-Blind MethodPruritusSeverity of Illness IndexTreatment Outcome

Substanzen

nemolizumabIL31RA protein, humanReceptors, InterleukinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • From Johns Hopkins Itch Center, Johns Hopkins University School of Medicine, Baltimore (S.G.K.); the Miami Itch Center, Miller School of Medicine at the University of Miami, Miami (G.Y.); the Department of Dermatology a…

ORCID-Profile: Sebastien Barbarot

Förderung

  • Galderma

Zitieren

APA

Kwatra, S. G., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., Naldi, L., Lynde, C., De Bruin-Weller, M. S., Nahm, W. K., Sauder, M., Gharib, R., Barbarot, S., Szepietowski, J. C., Conrad, C., Fleischer, A., Laquer, V. T., Misery, L., Serra-Baldrich, E., …, & OLYMPIA 2 Investigators (2023). Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. New England Journal of Medicine, 389(17), 1579-1589. https://doi.org/10.1056/nejmoa2301333

Vancouver

Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. New England Journal of Medicine. 2023;389(17):1579-1589. doi:10.1056/nejmoa2301333

BibTeX
@article{Kwatra2023,
  author = {Kwatra, Shawn G and Yosipovitch, Gil and Legat, Franz J and Reich, Adam and Paul, Carle and Simon, Dagmar and Naldi, Luigi and Lynde, Charles and De Bruin-Weller, Marjolein S and Nahm, Walter K and Sauder, Maxwell and Gharib, Rola and Barbarot, Sebastien and Szepietowski, Jacek C and Conrad, Curdin and Fleischer, Alan and Laquer, Vivian T and Misery, Laurent and Serra-Baldrich, Esther and Lapeere, Hilde and Ahmad, Faiz and Jabbar Lopez, Zarif K and Piketty, Christophe and Ständer, Sonja and OLYMPIA 2 Investigators, OLYMPIA 2 Investigators},
  title = {Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {17},
  pages = {1579--1589},
  doi = {10.1056/nejmoa2301333}
}
Kostenlos starten →